Eleison Pharmaceuticals

Eleison Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing late-stage therapies (in Phase II or III trials) to treat rare and life-threatening diseases such as pancreatic cancer, small cell lung cancer, pediatric bone cancer, and brain cancer. The company has obtained orphan drug designation for its first candidate drug, EPI-743, in both the United States and Europe. Vincerinone is currently in Phase II clinical development and is being evaluated for multiple clinical indications.